Alexion Pharmaceuticals, Inc. (ALXN) announced Thursday the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ALXN1210, its investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
from RTT - Biotech https://ift.tt/2yPBvQZ
via IFTTT
No comments:
Post a Comment